The short version of HGF mimetic fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-07-29 and is reviewed periodically as new material appears.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Derived from an angiotensin IV sequence. |
| Appearance | White to off-white powder | Typical for lyophilized research peptides. |
| Solubility | Soluble in dimethyl sulfoxide; sparingly in water | Exact aqueous solubility depends on salt form and purity. |
| Typical storage temperature | -20 °C or below | Desiccated and protected from light for long-term storage. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary in catalog listings. |
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
In August 1950, the Lao Prince Souphanouvong convened the first congress of the Pathet Lao, which was supported by Viet Minh and served as the vehicle for the communist challenge to French rule. On 13 August 1950, he was elected President of the Congress of the Pathet Lao, which met at the Việt Minh headquarters in Tuyen Quang, North Vietnam. In 1953, Pathet Lao fighters accompanied an invasion of Laos from Vietnam led by Viet Minh forces; they established a government at Viengxay in Houaphanh province, northeast Laos.
== Post-parliamentary career (2024–present) == In June 2025, Galloway renounced his opposition to Scottish independence, saying that he would now be in favour of a second referendum. Writing on X, he said: “We support the right of the Scots to self-determination. Eleven years after they last did so we believe the time for another referendum is close. Given the collapsing authority of the British state, the pitiful prime minister Starmer and the moral decline of British society, the result cannot easily be predicted. Britain has become a cesspit." This followed a comment Galloway had made on X in September 2024, in which he said: "You COULD persuade me to Scottish Independence, you could never persuade me to the SNP." In August 2025, Galloway announced that he would be contesting the 2026 Scottish Parliament election as the Workers Party candidate for Glasgow Southside. Additionally, he said that he would be second on the party list for the Glasgow region. In a press conference shortly after his election as MP for Rochdale in February 2024, Galloway had said that he was "no longer involved in Scottish politics", though did mention his support of the SNP's stance on Gaza, adding that they had been “outstanding on the Gaza question, at least by comparison with the two big parties of the state”. In light of this, he revealed that friend and lead candidate for Glasgow, Yvonne Ridley, had persuaded him to stand.
6-Aminoquinolyl-N-hydroxysuccinimidyl carbamate (AQC) is a fluorogenic, amine labeling dye that is not fluorescent itself, but covalently reacts with secondary amines to form a fluorescently labeled product. It has a fluorescence excitation wavelength of 250 nm (UV-C), and emission wavelength of 395 nm (deep violet, near UV).
Sources: en.wikipedia.org
In contrast, some infectious agents such as the Feline leukemia virus, are able to withstand immune responses and are capable of achieving long-term residence within an individual host, whilst also retaining the ability to spread into successive hosts. Virulence refers to the ability of an organism to invade a host and cause disease. Virulence factors are molecules that enable bacteria to attach to and invade the host's cells. These factors can be secreted, featured on the membrane, or located inside the cell (cytosolic). Cytosolic factors help bacteria rapidly adapt their metabolic, physical, and structural characteristics. Membrane-bound factors help bacteria adhere to the host and avoid detection by the host's immune system. Secreted factors assist bacteria to overcome the body's innate and adaptive immune defenses. In extracellular threats, secreted factors work together to destroy host cells.
== Overview == Several copper(II)-peptide complexes occur naturally. In human plasma, the level of GHK-Cu is about 200 ng/ml at age 20. By the age of 60, the level drops to 80 ng/ml. In humans, GHK-Cu is proposed to promote wound healing, attraction of immune cells, antioxidant and anti-inflammatory effects, stimulation of collagen and glycosaminoglycan synthesis in skin fibroblasts and promotion of blood vessels growth. Recent studies revealed its ability to modulate expression of a large number of human genes. Synthetic GHK-Cu is used in cosmetics as a reparative and anti-aging ingredient.
Cardiac muscle cells are the contracting cells that allow the heart to pump. Each cardiomyocyte needs to contract in coordination with its neighboring cells - known as a functional syncytium - working to efficiently pump blood from the heart, and if this coordination breaks down then – despite individual cells contracting – the heart may not pump at all, such as may occur during abnormal heart rhythms such as ventricular fibrillation. Viewed through a microscope, cardiac muscle cells are roughly rectangular, measuring 100–150μm by 30–40μm. Individual cardiac muscle cells are joined at their ends by intercalated discs to form long fibers. Each cell contains myofibrils, specialized protein contractile fibers of actin and myosin that slide past each other. These are organized into sarcomeres, the fundamental contractile units of muscle cells. The regular organization of myofibrils into sarcomeres gives cardiac muscle cells a striped or striated appearance when looked at through a microscope, similar to skeletal muscle. These striations are caused by lighter I bands composed mainly of actin, and darker A bands composed mainly of myosin. Cardiomyocytes contain T-tubules, pouches of cell membrane that run from the cell surface to the cell's interior which help to improve the efficiency of contraction. The majority of these cells contain only one nucleus (some may have two central nuclei), unlike skeletal muscle cells which contain many nuclei.
Sources: en.wikipedia.org
Fluoxetine has been shown to inhibit acid sphingomyelinase, a key regulator of ceramide levels which derives ceramide from sphingomyelin. Fluoxetine has a direct interaction with Tropomyosin receptor kinase B (TrkB), in which fluoxetine binds to the cholesterol site on TrkB, which "facilitates" Brain-derived neurotrophic factor signalling and reduces the amount of TrkB in a inactive state. This action also raises the surface expression of TrkB receptors.
Peripherally acting μ-opioid receptor antagonists (PAMORAs) are a class of chemical compounds that are used to reverse adverse effects caused by opioids interacting with receptors outside the central nervous system (CNS), mainly those located in the gastrointestinal tract. PAMORAs are designed to specifically inhibit certain opioid receptors in the gastrointestinal tract and with limited ability to cross the blood–brain barrier. Therefore, PAMORAs do not affect the analgesic effects of opioids within the central nervous system.
=== Advancing women in academia === Masur aims to advance and increase the visibility of women in STEMM. She uses her voice to create opportunities for women in science and fights for more equitable academic space. During her tenure at Mount Sinai, Masur was the first Dean of Faculty Developmencreating mentorship opportunities for women and men . She is a member of the Office of Gender Equity as Director of the Office for Women's Careers, which evolved from the Women Faculty Group at Mount Sinai (established in 1986). As the Director of the Office of Women's Careers, she advocates for women at ISMMS. Targeted programs and monthly events are hosted for women to discuss juggling career with family and to provides them with mentorship and leadership opportunities. Masur has published works describing the development of Women in Cell Biology (WICB) as well as anticipations of the future of women in STEMM. Masur held leadership roles including Chair of Diversity Issues Committee on Women and Minorities for the Association for Research in Vision and Ophthalmology from 1997 to 1999, co-director of the National Eye Institute's "Fundamental Issues in Vision Research" at the Marine Biological Laboratory from 2001 to 2010, and Chair of Women in Cell Biology for the American Society of Cell Biology from 2010 to 2016. In 2015 the American Society for Cell Biology honored Masur by naming one of their leadership awards the "Sandra K. Masur Senior Leadership Award" for efforts in scientific leadership and her long history of creating opportunities for women.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.
No major regulatory agency has approved dihexa as a therapeutic product. Human safety and efficacy data are limited. Its sale as a research chemical does not constitute approval for medical use.
Some animal and cell studies report synaptic or cognitive effects, which has led to nootropic framing online. These findings are preliminary and have not been confirmed in robust human trials. The term nootropic is not a regulatory category.
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.